Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Depression
Interventions: Cognitive-behavioral group, Cognitive-behavioral bibliotherapy; Behavioral
Lead sponsor: Oregon Research Institute; Other
Eligibility: 13 Years to 19 Years
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Carcinoma, Hepatocellular
Interventions: Onartuzumab, Sorafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Sarasota, Florida • Baltimore, Maryland • New York, New York + 2 more

Conditions: Suicide
Interventions: PC CARES; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 15 Years and older
Enrollment: 1,427 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Office Hysteroscopy and Endometrial Biopsy
Interventions: Misoprostol 50 mcg pesssary, Placebos; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years to 70 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions: CTX001; Biological
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years to 35 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 6
States / cities: Palo Alto, California • Chicago, Illinois • New York, New York + 2 more

Conditions: Recurrent Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
Interventions: Lumber Puncture, Blood Specimen Collection, Magnetic resonance imaging (MRI), Gemcitabine, Paxalisib, Tumor Biopsy; Procedure · Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 39 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Seattle, Washington

Conditions: Healthy
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Diabetic Retinopathy
Interventions: AEYE Software Device; Device
Lead sponsor: AEYE Health Inc; Industry
Eligibility: 22 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions: MCS110, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 2 Years and older · Male only
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 12
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 9 more

Conditions: Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions: Not listed
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: Not listed
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Breast Benign, Malignant Neoplasm of Breast, Breast Malignant Tumor
Interventions: Magnetic Resonance Imaging (MRI); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Fatigue
Interventions: Energy Conservation Work Simplification Education; Behavioral
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Breastfeeding Self-Efficacy, Breastfeeding Continuation, Breastfeeding Duration, Breastfeeding Support
Interventions: Peer counseling, Additional funds; Behavioral
Lead sponsor: University of North Carolina, Greensboro; Other
Eligibility: 5 Days and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Greensboro, North Carolina

Conditions: Multiple Sclerosis
Interventions: MBCT, CBT; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Dyslipidemia
Interventions: Evacetrapib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Type 2 Diabetes Mellitus
Interventions: Efpeglenatide, Dulaglutide, Background therapy Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 908 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 30
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 25 more

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
Interventions: Non-interventional; Other
Lead sponsor: Innoviva Specialty Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Sacramento, California • Gainesville, Florida • Tampa, Florida + 9 more

Conditions: Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
Interventions: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 1,394 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more

Conditions: Angelman Syndrome
Interventions: No intervention, GTX-102; Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year to 64 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 5 more

Conditions: Healthy Volunteer
Interventions: ABBV-101; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Chronic Pain, Depression, PTSD, Injuries, Illness, Chronic, Physical Disability
Interventions: Resilience and Well-Being Program; Behavioral
Lead sponsor: VA Puget Sound Health Care System; Federal
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lymphoma
Interventions: Molecular Functional Portrait; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostatic Neoplasms
Interventions: Radiotherapy, LHRHa, Apalutamide; Radiation · Drug
Lead sponsor: Janssen Pharmaceutica N.V., Belgium; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 13
States / cities: Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more

Search by objective public record fields.

Testing the Effectiveness of Adolescent Depression Prevention Programs (The OregonBlues Study)

A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

Promoting Community Conversations About Research to End Native Youth Suicide in Rural Alaska

Misoprostol in Office Hysteroscopy and Endometrial Biopsy

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

A Study of Lasmiditan in Healthy Japanese and Caucasian Participants

Efficacy and Safety of AEYE-DS Software Device for Automated Detection of Diabetic Retinopathy From Digital Fundus Images

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.

Low-field MRI for Breast Cancer Screening

Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors

Breastfeeding Intervention to Prevent Obesity Among Children

MBCT and CBT for Chronic Pain in Multiple Sclerosis

A Study of Evacetrapib in Participants With Abnormal Cholesterol

Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

Resilience and Well-Being Pilot Study

Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma

A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer